Drug Search Results
More Filters [+]

Indatuximab ravtansine

Alternative Names: indatuximab ravtansine, bt-062, bt062, bt 062
Latest Update: 2023-07-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: SDC Inhibitor

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Biotest
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Indatuximab ravtansine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Multiple Myeloma|Triple Negative Breast Cancer|Bladder Cancer|Transitional Cell Carcinoma

Phase 1: Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01638936

P2

Completed

Multiple Myeloma

2018-10-30

53%

INTRAIN-BB (INdaTuximab RAvtansin effect IN Breast and Bladder cancer)

P2

Completed

Triple Negative Breast Cancer|Bladder Cancer|Transitional Cell Carcinoma

2017-08-04

NCT01001442

P2

Completed

Multiple Myeloma

2014-07-01

NCT00723359

P1

Completed

Multiple Myeloma

2012-04-01

Recent News Events